TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28535809
Drug: Rosiglitazone (0.045
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (0.045 mg/kg/dose) twice daily for 4 days
Study: 25979561
Drug: 500 cc
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 cc Saline by rectal enema
Study: 25979561
Drug: six bisacodyl
Normalized name: Bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: six bisacodyl tablets
Study: 23490325
Drug: Epimacular brachytherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epimacular brachytherapy (EMBT) with 2 mandated monthly ranibizumab injections followed by pro re nata (PRN) ranibizumab
Study: 23490325
Drug: 3 mandated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mandated monthly ranibizumab injections followed by mandated quarterly plus PRN ranibizumab
Study: 16937963
Drug: Ribose (625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribose (625 mg)
Study: 15309425
Drug: Transdermal progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal progesterone (TPD+)
Study: 15309425
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of soy+ and TPD+
Study: 15309425
Drug: Placebo (isoflavone-poor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (isoflavone-poor soymilk and progesterone-free cream)
Study: 20199137
Drug: Liraglutide (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (0.9 mg once daily)
Study: 20199137
Drug: Glibenclamide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (2.5 mg/day, once or twice daily)
Study: 15639169
Drug: 21-mg transdermal
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 21-mg transdermal nicotine patch (smokers)
Study: 15639169
Drug: 7-mg transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-mg transdermal nicotine patch (nonsmokers)
Study: 12860725
Drug: Chemokine antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Chemokine antagonist
Study: 1997083
Drug: Bupivacaine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (40 ml of 0.25%)
Study: 1997083
Drug: Saline (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (40 ml)
Study: 6392105
Drug: Intravenous acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous acyclovir (30 mg/kg per day for five days)
Study: 31122212
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate plus prednisone (AAP) and Androgen Deprivation Therapy (ADT)
Study: 31122212
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of AAP (without ADT) and apalutamide
Study: 29789507
Drug: Caffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated coffee (CAF) consumption (5.5 mg/kg of caffeine)
Study: 24981585
Drug: Endovenous steam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovenous steam ablation (EVSA) high dose
Study: 19237660
Drug: Salsalate (4500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salsalate (4500 mg/d)
Study: 12234030
Drug: Direct anterior
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct anterior electron field treatment
Study: 12234030
Drug: Tangential photon
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tangential photon treatment
Study: 9620901
Drug: Intranasal cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal cold dry air (CDA)
Study: 7988978
Drug: Cefotaxime i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime i.v. followed by Cefixime oral (2 x 2 g cefotaxime i.v. for 7 to 10 days, then 1 x 400 mg cefixime for 5 to 8 days)
Study: 7988978
Drug: Cefotaxime parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime parenteral (2 x 2 g cefotaxime for 48 to 72 hours)
Study: 7988978
Drug: Cefotaxime i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime i.v. followed by Cefixime oral
Study: 7988978
Drug: Cefotaxime parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime parenteral
Study: 2590626
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate (CBS) administered twice daily (Group A)
Study: 2590626
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate (CBS) administered four times a day (Group B)
Study: 25764916
Drug: Pre-procedure spinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-procedure spinal ultrasound (US) to determine the optimal lumbar level for injection
Study: 25764916
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group determined the level of injection by palpation
Study: 24147175
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo treatment during pregnancy)
Study: 19422464
Drug: Glucose levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose levels in the second quartile (5.3-5.7 mmol L(‐1))
Study: 19422464
Drug: Glucose levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose levels in the third quartile (5.7-6.6 mmol L(‐1))
Study: 19422464
Drug: Glucose levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose levels in the fourth quartile (>= 6.6 mmol L(‐1))
Study: 9551672
Drug: Phlebotomy (500-ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phlebotomy (500-ml every 2 weeks until iron deficiency achieved) followed by 6-month course of alpha-interferon 2b (3 mu tiw)
Study: 9551672
Drug: Phlebotomy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phlebotomy followed by interferon therapy
Study: 7817727
Drug: Women with
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women with medical treatment for essential hypertension
Study: 21199410
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 added to systemic steroid treatment for 2 weeks.
Study: 21199410
Drug: Systemic steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic steroid treatment for 2 weeks (control group).
Study: 12201869
Drug: INF-alpha 10
Normalized name: r-INF-alpha
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: INF-alpha 10 MU/m2 and LAM 4 mg/kg (max 100 mg) for 6 months, then LAM alone for 6 months
Study: 2248073
Drug: Moclobemide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (300 mg daily for the first 5 days, then up to 600 mg)
Study: 2248073
Drug: Imipramine (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (starting at 33 mg, increased to 100 mg/day in the first 5 days, then could be further increased)
Study: 26411328
Drug: Mitiglinide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitiglinide (10 mg tid) with insulin glargine
Study: 26411328
Drug: Voglibose (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voglibose (0.2 mg tid) with insulin glargine
Study: 23181446
Drug: Global secondary
Normalized name: Secondary potassium phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Global secondary low back pain prevention program (two-hour information session + five weekly 90-min exercise sessions)
Study: 11994812
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of exercise and lifestyle modification
Study: 9816650
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 60 micrograms PGE1 over a period of 2 hours
Study: 7694917
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality graded exposure treatment (N = 10)
Study: 28107559
Drug: AVX001 (cPLA2α
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVX001 (cPLA2α inhibitor) at 5% dose level
Study: 28107559
Drug: AVX001 (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVX001 (combined doses of 3% and 5%)
Study: 28107559
Drug: AVX001 (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVX001 (any dose)
Study: 19342174
Drug: tricyclic antidepressant
Normalized name: Tricyclic antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: tricyclic antidepressant medication
Study: 19342174
Drug: (cognitive-behavioral) stress-management
Approvals — FDA: no, EMA: no, PMDA: no
Description: (cognitive-behavioral) stress-management therapy plus placebo
Study: 19342174
Drug: stress-management therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: stress-management therapy plus antidepressant medication
Study: 15869575
Drug: High-intensity warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity warfarin (INR range 3.0-4.5)
Study: 15869575
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (warfarin, INR range 2.0-3.0 or aspirin 100 mg/day)
Study: 9585282
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine 6.6 mg combined with sufentanil 3.3 microg
Study: 9585282
Drug: Plain bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain bupivacaine 6.6 mg combined with sufentanil 3.3 microg
Study: 2696203
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg (oral)
Study: 2696203
Drug: Verapamil 1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 1.6 mg (inhalation)
Study: 11565519
Drug: Irbesartan 150
Normalized name: irbesartan 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 150 mg daily
Study: 15655140
Drug: 6% salicylic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% salicylic acid gel plus 0.1% tacrolimus ointment
Study: 15655140
Drug: 6% salicylic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% salicylic acid gel plus vehicle
Study: 11860410
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori eradication treatment in H. pylori-positive patients (36 patients)
Study: 2297284
Drug: 600 mg/d
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/d cholesterol diet
Study: 2297284
Drug: 200 mg/d
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/d cholesterol diet
Study: 856917
Drug: H3ChN2Ch virus
Normalized name: rubella virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: H3ChN2Ch virus vaccine
Study: 856917
Drug: Heq1N2Ch virus
Normalized name: rubella virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heq1N2Ch virus vaccine
Study: 22876748
Drug: Doxycycline 200
Normalized name: doxycycline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 200 mg for three weeks
Study: 20712805
Drug: morphine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 0.1 mg.kg⁻¹
Study: 20712805
Drug: oxycodone 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxycodone 0.05 mg.kg⁻¹
Study: 20712805
Drug: oxycodone 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxycodone 0.1 mg.kg⁻¹
Study: 20712805
Drug: oxycodone 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxycodone 0.2 mg.kg⁻¹
Study: 11192337
Drug: Biofeedback-assisted behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback-assisted behavioral treatment
Study: 11192337
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment with oxybutynin chloride
Study: 3166825
Drug: All program
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All program components (lifestyle assessment, physician prescription of lifestyle change, educational materials)
Study: 26392433
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of autologous bone marrow mononuclear cells (BMNC)
Study: 23723385
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with conventional physical therapy
Study: 21700945
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (perindopril plus indapamide for eligible patients)
Study: 3451878
Drug: Alinidine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alinidine (10 mg i.v. bolus followed by 10 mg h-1 infusion)
Study: 24402830
Drug: Lapatinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib plus vinorelbine (1,250 mg orally QD continuously plus 20 mg/m(2)/day IV)
Study: 24402830
Drug: Lapatinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib plus capecitabine (1,250 mg orally QD continuously plus 2,000 mg/m(2)/day orally, 2 doses)
Study: 16456382
Drug: Alpha‐1‐antitrypsin replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha‐1‐antitrypsin replacement therapy
Study: 12641014
Drug: Paclitaxel-coated drug-eluting
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel-coated drug-eluting stent
Study: 12641014
Drug: Paclitaxel-coated drug-eluting
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel-coated drug-eluting stent (NIRx, TAXUS I trial)
Study: 2576115
Drug: Acebutolol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (400 mg u.i.d.)
Study: 2576115
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg u.i.d.)
Study: 577889
Drug: Two-agent therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-agent therapy (methotrexate and hydrocortisone)
Study: 577889
Drug: Three-agent therapy
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-agent therapy (methotrexate, hydrocortisone, and cytosine arabinoside)
Study: 577889
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of two-agent and three-agent therapy
Study: 7044582
Drug: albendazole 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: albendazole 0.4 g (adolescents and adults) or 0.2 g (children)
Study: 31029925
Drug: Organic beet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organic beet leaves and stalk juice (32 mg EAG/100 mL)
Study: 31029925
Drug: Organic beet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organic beet leaves and stalk juice (77.5 mg EAG/100 mL)
Study: 29322254
Drug: Thermal mineral
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal mineral water treatment for 3 weeks (15 occasions) on top of usual musculoskeletal pain killer treatment
Study: 29322254
Drug: Traditional musculoskeletal
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional musculoskeletal pain killer treatment
Study: 18436468
Drug: No-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control group (Control)
Study: 1253157
Drug: Transfer factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfer factor immunotherapy
Study: 29130724
Drug: Probiotics therapy
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics therapy for eight weeks
Study: 9440718
Drug: Sequential MOPP-ABVD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential MOPP-ABVD
Study: 7866845
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy with cortisone injections
Study: 7866845
Drug: Standardised conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised conventional and optimised activating treatment
Study: 2712914
Drug: Endocervical application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocervical application of 0.4 mg prostaglandin E2 (PGE2) gel
Study: 2712914
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin infusions
Study: 28289033
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of PZA (>50 mg/kg of body weight)
Study: 28289033
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of PZA (>80 mg/kg)
Study: 28289033
Drug: Doses in
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses in the range of 30 to 40 mg/kg of PZA
Study: 23154555
Drug: First-line erlotinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy
Study: 19922895
Drug: Orally disintegrating
Normalized name: Clozapine Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally disintegrating tablet (ODT) 5-mg finasteride
Study: 19922895
Drug: Standard tablet
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard tablet 5-mg finasteride
Study: 17966839
Drug: Single-dose lonafarnib
Normalized name: lonafarnib
DrugBank: Lonafarnib (DB06448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose lonafarnib 100 mg under fasted conditions
Study: 17966839
Drug: Single-dose lonafarnib
Normalized name: lonafarnib
DrugBank: Lonafarnib (DB06448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose lonafarnib 100 mg under fed conditions
Study: 17966839
Drug: Multiple-dose lonafarnib
Normalized name: lonafarnib
DrugBank: Lonafarnib (DB06448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple-dose lonafarnib 200 mg Q 12 H for 28 days under fasted conditions
Study: 17966839
Drug: Multiple-dose lonafarnib
Normalized name: lonafarnib
DrugBank: Lonafarnib (DB06448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple-dose lonafarnib 200 mg Q 12 H for 28 days under fed conditions
Study: 14987883
Drug: Autologous renal
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous renal tumour cell vaccine (six intradermal applications at 4-week intervals postoperatively)
Study: 14987883
Drug: Autologous renal
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous renal tumour cell vaccine
Study: 29389076
Drug: Bazedoxifene (20-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bazedoxifene (20-mg capsule)
Study: 29389076
Drug: Ibuprofen (600-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (600-mg tablet)
Study: 29389076
Drug: Bazedoxifene and
Normalized name: Bazedoxifene and conjugated estrogen only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bazedoxifene and Ibuprofen (combined)
Study: 18285414
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose l-T(4) (subclinical thyrotoxicosis arm)
Study: 18285414
Drug: Usual dose
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual dose l-T(4) (euthyroid arm)
Study: 15871089
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Tl‐weighted and STIR sequences
Study: 8721699
Drug: Straight pigtail
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Straight pigtail catheter with preset injection rate (Group IA, n = 46)
Study: 8721699
Drug: Curved pigtail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curved pigtail catheter with preset injection rate (Group IIA, n = 48)
Study: 8721699
Drug: Straight pigtail
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Straight pigtail catheter with operator defined injection rate (Group IB, n = 49)
Study: 8721699
Drug: Curved pigtail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curved pigtail catheter with operator defined injection rate (Group IIB, n = 45)
Study: 27716253
Drug: Nurse-administered IVI
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-administered IVI
Study: 27716253
Drug: Physician-administered IVI
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician-administered IVI
Study: 21183910
Drug: cytoflavin intravenously
Approvals — FDA: no, EMA: no, PMDA: no
Description: cytoflavin intravenously in dose 10 ml/day for 5 days
Study: 21183910
Drug: standard intensive
Normalized name: MACADAMIA OIL 2 g in 100 g / CERAMIDE NP 0.0006 g in 100 g / PANTHENOL 0.75 g in 100 g / CENTELLA ASIATICA WHOLE 0.003 g in 100 g TOPICAL CREAM [ATO STANDARD INTENSIVECREAM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard intensive therapy for burns
Study: 8774297
Drug: Negative media
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative media with < 1 pg/mL of endotoxin
Study: 8774297
Drug: Positive media
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive media with > or = 1 pg/mL of endotoxin
Study: 8774297
Drug: Media with
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Media with > 2 pg/mL of endotoxin
Study: 1309477
Drug: 12 g
Normalized name: PEG-12 GLYCERYL LAURATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g citrus pectin added to a 500 kcal meal with 25 mg beta-carotene
Study: 1309477
Drug: Control meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control meal (500 kcal) with 25 mg beta-carotene without pectin
Study: 6368491
Drug: Regional radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regional radiotherapy (RT) followed by weekly injection of vinblastine for 2 years
Study: 6368491
Drug: Extended RT
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended RT (mantle + para‐aortic + spleen treatment)